A Peptide from Kefir Lowered Blood Pressure and Protected Blood Vessels in Hypertensive Mice
Kef-1, an ACE-inhibiting peptide derived from kefir fermentation, reduced blood pressure, oxidative stress, and vascular damage in a mouse model of hypertension.
Quick Facts
What This Study Found
Kef-1 peptide reduced ROS production and improved vascular structure in 2K1C mice.
Key Numbers
How They Did This
The study used an angiotensin II-dependent hypertension model in 2K1C mice to evaluate the effects of Kef-1.
Why This Research Matters
Understanding how Kef-1 works could lead to new treatments for hypertension and related cardiovascular diseases. This research highlights the potential of natural compounds in managing health conditions.
The Bigger Picture
Food-derived bioactive peptides — from kefir, milk, fish, and other sources — are an increasingly active area of research in cardiovascular health. ACE-inhibitory peptides produced during fermentation may partly explain why fermented dairy consumption is associated with lower blood pressure in observational studies. Kef-1 adds to a growing library of food peptides that could become nutraceutical interventions for hypertension.
What This Study Doesn't Tell Us
The study was conducted in mice, and results may not directly translate to humans. Further research is needed to confirm efficacy in human populations.
Questions This Raises
- ?Does drinking kefir provide enough Kef-1 to produce meaningful blood pressure effects in humans?
- ?How does Kef-1's ACE inhibitory potency compare to prescription ACE inhibitors like lisinopril?
- ?Could Kef-1 be developed as a nutraceutical supplement for mild hypertension?
Trust & Context
- Key Stat:
- ACE inhibitor from kefir Kef-1 inhibits the same enzyme targeted by prescription blood pressure drugs, and showed anti-hypertensive effects in a mouse model
- Evidence Grade:
- This is a preclinical study using a well-established mouse model of hypertension (2K1C) with both in vivo and in vitro components. The 'Preliminary' grade reflects that while the animal results are promising, no human data exists for Kef-1 specifically.
- Study Age:
- Published in 2022 in Food & Function, this is a recent study in the growing field of food-derived bioactive peptides. The findings are current and reflect modern analytical approaches to nutraceutical research.
- Original Title:
- Use of kefir peptide (Kef-1) as an emerging approach for the treatment of oxidative stress and inflammation in 2K1C mice.
- Published In:
- Food & function, 13(4), 1965-1974 (2022)
- Authors:
- Aires, Rafaela, Gobbi Amorim, Fernanda, Côco, Larissa Zambom, da Conceição, Amanda Pompermayer, Zanardo, Tadeu Ériton Caliman, Taufner, Gabriel Henrique, Nogueira, Breno Valentim, Vasquez, Elisardo Corral, Melo Costa Pereira, Thiago, Campagnaro, Bianca Prandi, Dos Santos Meyrelles, Silvana
- Database ID:
- RPEP-05968
Evidence Hierarchy
Frequently Asked Questions
What is Kef-1 and how does it relate to drinking kefir?
Kef-1 is a specific peptide produced when kefir bacteria and yeast ferment milk proteins. It acts as a natural ACE inhibitor — blocking the same enzyme that prescription blood pressure drugs target. While drinking kefir exposes you to many bioactive peptides including Kef-1, it's unclear how much active Kef-1 survives digestion and reaches the bloodstream in meaningful amounts.
Could this peptide replace blood pressure medication?
Not based on current evidence. This is a mouse study showing promising results, but no human trials have been conducted with isolated Kef-1. Prescription ACE inhibitors have decades of clinical data supporting their use. However, food-derived ACE-inhibiting peptides like Kef-1 could potentially serve as complementary approaches to blood pressure management or as preventive nutraceuticals.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-05968APA
Aires, Rafaela; Gobbi Amorim, Fernanda; Côco, Larissa Zambom; da Conceição, Amanda Pompermayer; Zanardo, Tadeu Ériton Caliman; Taufner, Gabriel Henrique; Nogueira, Breno Valentim; Vasquez, Elisardo Corral; Melo Costa Pereira, Thiago; Campagnaro, Bianca Prandi; Dos Santos Meyrelles, Silvana. (2022). Use of kefir peptide (Kef-1) as an emerging approach for the treatment of oxidative stress and inflammation in 2K1C mice.. Food & function, 13(4), 1965-1974. https://doi.org/10.1039/d1fo01798e
MLA
Aires, Rafaela, et al. "Use of kefir peptide (Kef-1) as an emerging approach for the treatment of oxidative stress and inflammation in 2K1C mice.." Food & function, 2022. https://doi.org/10.1039/d1fo01798e
RethinkPeptides
RethinkPeptides Research Database. "Use of kefir peptide (Kef-1) as an emerging approach for the..." RPEP-05968. Retrieved from https://rethinkpeptides.com/research/aires-2022-use-of-kefir-peptide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.